Navigation Links
XTL Announces Delisting From the Official List of the United Kingdom Listing Authority
Date:10/31/2007

Processing Fees on Transfer of Ordinary Shares Into ADRs to be Waived for

an Additional Month

VALLEY COTTAGE, New York, October 31 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTL) today announced that the Company's ordinary shares have been delisted from the Official List of the United Kingdom Listing Authority, pursuant to the October 2, 2007 vote at the Company's Extraordinary General Meeting. With the cancellation of the listing on the London Stock Exchange, shareholders may deposit their ordinary shares with the Company's depositary bank, The Bank of New York, in exchange for American Depositary Receipts, or ADRs, which are traded on NASDAQ, or trade their ordinary shares on the TASE.

XTL Biopharmaceuticals Ltd. has further announced that issuances of ADRs by The Bank of New York will be processed free of the customary charges of The Bank of New York for an additional month, through November 30, 2007. The Bank of New York will issue ADRs representing American Depositary Shares, or ADSs, if shareholders or their broker deposit Ordinary Shares with The Bank of New York's Custodian, either the Tel Aviv office of Bank Hapoalim B.M., or the London office of The Bank of New York. One ADR will represent an ownership interest in ten of the Company's Ordinary Shares.

Interested investors should contact their brokers to discuss the waived fee and, should they have any questions, can contact The Bank of New York in either London or New York as follows:

London:

Mark Lewis,

Vice President,

Tel +44(0)20-7964-6089,

Fax +44(0)20-7964-6024,

marlewis@bankofny.com

New York:

Jason Paltrowitz,

Vice President,

Tel +1-212-815-2077,

Fax +1-212-815-3004,

jpaltrowitz@bankofny.com

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain. XTL is also developing several novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; TASE: XTL).

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating continued undisrupted trading of the Company's ADRs on NASDAQ and similar matters, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Risk factors that could adversely affect our operations are identified from time to time in our reports filed with the Securities and Exchange Commission, including our annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2007. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.xtlbio.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only. This press release is for informational purposes only and is not an offer to by or the solicitation of an offer to sell any securities.

Contact:

Ron Bentsur,

Chief Executive Officer

Tel: +1-845-267-0707 ext. 225


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... International Protein, ... nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in Hilton ... and nutritional scientist who was determined to create a line of products that would ...
(Date:1/20/2017)... ... , ... “Mary Magdalene: Grace is Greater than Sin”: a unique and ... Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation of published ... with countless women who had little knowledge of the female characters portrayed in the ...
(Date:1/20/2017)... Farmville, NC (PRWEB) , ... January 20, 2017 ... ... the vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in ... article by Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive ...
(Date:1/20/2017)... ... 20, 2017 , ... “The Land of More and More”: a brilliant ... hunger, and shares the simple and achievable answer. “The Land of More and More” ... Fairview Missionary Church in Angola, Indiana where he works with the children’s ministry department. ...
(Date:1/19/2017)... ... 19, 2017 , ... Next week after January 20th, the fear for many ... that circumvent health needs of over 30 million. Many interviews with Dr. Carol Francis ... government public servants were suppose to prioritize. Interviews provided below. , Among ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
(Date:1/19/2017)... January 19, 2017 According to a study ... is set to witness a CAGR of 6.5% during the forecast ... will continue to be the leading market for cryotherapy globally ... ... emphasizing on ensuring affordable and adequate supply of gas in order ...
Breaking Medicine Technology: